Lv51
890 积分 2024-10-24 加入
Disproportionality analysis of dermatologic adverse events associated with nirogacestat: Insights from the U.S. Food and Drug Administration Adverse Event Reporting System
4天前
已完结
Emerging Safety Signals of Sonidegib Hedgehog Inhibition for Basal Cell Carcinoma: A Real-World Analysis from the FDA Adverse Event Reporting System (FAERS)
4天前
已完结
Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
27天前
已完结
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
1个月前
已完结
Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial
1个月前
已完结
Bridging the dimensional gap from planar spatial transcriptomics to 3D cell atlases
3个月前
已完结
Antihypertensives and Skin Cancer: Evidence from FAERS
3个月前
已关闭
Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis
3个月前
已完结
Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events
3个月前
已完结
皖公网安备34019202002308
